Most Americans support psilocybin use for mental health and well-being, a new study shows, marking a shift in attitudes toward psychedelics.
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...
The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...
Because these trips are so bizarre, even compared to other psychedelics, DMT has largely lived on the fringes of the ongoing ...
Among this demographic, psychotic disorders alone contribute to 25 per cent of the total disease burden, with schizophrenia ...
In 2022, when Ms Evelyn Yeo learnt about a family who had made a donation to the local brain bank – the first in South-east ...
US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights.EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
Research suggests relapses can lead to harm, reduce the quality of life, and have a heavy economic impact on patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback